Published in JAMA Network Open · View the paper (DOI)
The COVID-19 pandemic has been linked to increased disparities in buprenorphine and naltrexone prescriptions for opioid use disorder among racial and ethnic minority groups. The study found that these groups experienced worsened disparities compared to white patients.
Coverage from 2 institutions